We investigated the P50 component as a biomarker of Alzheimer壮s disease (AD).
Participants included non-demented patients with mild cognitive impairment (MCI).
P50 amplitude was larger in amyloid-positiverelative to amyloid–negative patients.
P50 amplitude predicted cerebrospinal fluid amyloid status in the MCI patients.
This is consistent with MCI to AD converters having shown larger P50 at baseline.
P50 may prove to be a useful biomarker for early, even pre-symptomatic, AD.